Independent Advisor Alliance’s NeuroSense Therapeutics NRSN Stock Holding History

Independent Advisor Alliance’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.8K	Buy	+50,000	New	+$44.6K	﹤0.01%	1569

Other funds holding NRSN

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Independent Advisor Alliance's NRSN Position: Q1 2026 in Review

Independent Advisor Alliance opened a new position in NeuroSense Therapeutics (NRSN) in Q1 2026: 50,000 shares worth $37.8K. The stake represents ﹤0.01% of the portfolio and ranks #1569 among its holdings.

13 funds tracked by Wall St. Rank hold NRSN as of Q1 2026.

Independent Advisor Alliance held 50,000 shares of NeuroSense Therapeutics worth $37.8K as of Q1 2026.
NeuroSense Therapeutics was a new Independent Advisor Alliance position in Q1 2026.
NeuroSense Therapeutics made up ﹤0.01% of Independent Advisor Alliance's portfolio in Q1 2026, its #1569 holding.
13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2026.

Based on Independent Advisor Alliance's 13F filing for Q1 2026, filed 12 May 2026.